Pharmaceuticals, Biotechnology and Life Sciences
PMV Pharmaceuticals, Inc., a cancer focused developer of p53-targeted small molecule drugs, has completed a Series B financing round bagging $74 million.
BD said on Wednesday that its BD Veritor System Flu A+B, a digital immunoassay for the rapid detection of influenza, meets the new Food and Drug Administration’s (FDA’s) performance requirements.
A UK-based private clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases, has triggered the phase 1/2a proof of concept study in the US of TOP1630 ophthalmic solution for the treatment of the dry eye syndrome.
Verona Pharma has made an important step in the phase two clinical trial for its candidate RPL554, used for chronic obstructive pulmonary disease (COPD). Namely, the first patient has been dosed testing RPL544 as an add-on therapy to tiotropium, Spiriva.
What does a healthy heart really mean? Is it just the physical heart muscle that matters, or is there an important emotional component?
And can the simple act of conveying your best wishes and intentions make a real difference in the health of the recipient’s heart — and even your own? What does the science say?
Bristol-Myers Squibb has entered into an ASR program with each of Morgan Stanley & Co. LLC and Goldman, Sachs & Co. to repurchase, in aggregate, $2 billion of Bristol-Myers Squibb’s common stock, and it has named three new directors.
Following a diet that mimics fasting may reduce risk factors for disease in generally healthy people, according to a small study.
Omnicell has bagged a deal with Inova, a not-for-profit healthcare system based in Northern Virginia, for its integrated software and services offering, Performance Center.
The American Brain Tumor Association (ABTA) has elected four new members to its Board of Directors in January, to bring the number of directors to thirteen.
AstraZeneca has entered into an agreement with TerSera Therapeutics for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada, an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.